WO2021203044A3 - High-throughput assay for circulating antibodies against severe acute respiratory syndrome coronavirus 2 - Google Patents

High-throughput assay for circulating antibodies against severe acute respiratory syndrome coronavirus 2 Download PDF

Info

Publication number
WO2021203044A3
WO2021203044A3 PCT/US2021/025640 US2021025640W WO2021203044A3 WO 2021203044 A3 WO2021203044 A3 WO 2021203044A3 US 2021025640 W US2021025640 W US 2021025640W WO 2021203044 A3 WO2021203044 A3 WO 2021203044A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
antibodies against
acute respiratory
respiratory syndrome
Prior art date
Application number
PCT/US2021/025640
Other languages
French (fr)
Other versions
WO2021203044A2 (en
Inventor
Susan Zolla-Pazner
Florian KRAMMER
Viviana Simon
Svenja WEISS
Original Assignee
Icahn School Of Medicine At Mount Sinai
The United States Government As Represented By The Department Of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Of Medicine At Mount Sinai, The United States Government As Represented By The Department Of Veterans Affairs filed Critical Icahn School Of Medicine At Mount Sinai
Publication of WO2021203044A2 publication Critical patent/WO2021203044A2/en
Publication of WO2021203044A3 publication Critical patent/WO2021203044A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present application relates to a high-throughput assay for circulating antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), including beads comprising a recombinant SARS-CoV-2 protein or epitope thereof; a kit comprising a population of beads, where each bead comprises a recombinant SARS-CoV-2 protein or epitope thereof and a detection reagent; a method for detecting the presence of antibodies in a subject that bind to a protein of SARS-CoV-2; and a method for assessing the efficacy of a vaccine which alters anti-SARS-CoV-2 protein antibody levels in a subject.
PCT/US2021/025640 2020-04-03 2021-04-02 High-throughput assay for circulating antibodies against severe acute respiratory syndrome coronavirus 2 WO2021203044A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063005191P 2020-04-03 2020-04-03
US63/005,191 2020-04-03
US202063029232P 2020-05-22 2020-05-22
US63/029,232 2020-05-22

Publications (2)

Publication Number Publication Date
WO2021203044A2 WO2021203044A2 (en) 2021-10-07
WO2021203044A3 true WO2021203044A3 (en) 2022-02-17

Family

ID=77929679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025640 WO2021203044A2 (en) 2020-04-03 2021-04-02 High-throughput assay for circulating antibodies against severe acute respiratory syndrome coronavirus 2

Country Status (1)

Country Link
WO (1) WO2021203044A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202307565D0 (en) 2020-04-22 2023-07-05 BioNTech SE Coronavirus vaccine
WO2023170173A1 (en) * 2022-03-08 2023-09-14 Complix Nv Polypeptides capable of inhibiting sars-cov-2 viruses
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095791A1 (en) * 2006-06-30 2008-04-24 New York University Recombinant HIV-1 gp120 Immunogen with Three Different V3 Loops from Viruses of Different Clades
EP1618127B1 (en) * 2003-04-10 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic composition comprising a spike protein of the SARS coronavirus
US20170096455A1 (en) * 2014-03-20 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
CA2687827C (en) * 2007-06-08 2017-08-29 Bio-Rad Pasteur Multiplex method for detecting an infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618127B1 (en) * 2003-04-10 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic composition comprising a spike protein of the SARS coronavirus
US20080095791A1 (en) * 2006-06-30 2008-04-24 New York University Recombinant HIV-1 gp120 Immunogen with Three Different V3 Loops from Viruses of Different Clades
CA2687827C (en) * 2007-06-08 2017-08-29 Bio-Rad Pasteur Multiplex method for detecting an infection
US20170096455A1 (en) * 2014-03-20 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID E. GORDON, JANG GWENDOLYN M., BOUHADDOU MEHDI, XU JIEWEI, OBERNIER KIRSTEN, O’MEARA MATTHEW J., GUO JEFFREY Z., SWANEY: "A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential DrugRepurposing", BIORXIV, 22 March 2020 (2020-03-22), pages 1 - 45, XP055726898, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf> [retrieved on 20200902], DOI: 10.1101/2020.03.22.002386 *
SEKIMUKAI, H ET AL.: "Gold nanoparticle-adjuvanted S protein induces a strong antigen specific IgG response against severe acute respiratory syndrome related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs", MICROBIOLOGY AND IMMUNOLOGY, vol. 64, no. 1, 18 November 2019 (2019-11-18), pages 33 - 51, XP055822197, [retrieved on 20200100], DOI: 10.1111/1348-0421.12754 *
WEISS, S ET AL.: "A High Through-Put Assay For Circulating Antibodies Directed Against The S Protein Of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", MEDRXIV, 17 April 2020 (2020-04-17), XP055905743, DOI: 10.1101/ 2020.04.14.20059501 *
ZHU, N ET AL.: "A Novel Coronavirus from Patients with Pneumonia in China", NEW ENGLAND JOURNAL OF MEDICINE, vol. 382, no. 8, 2019, pages 727 - 733, XP055810616, [retrieved on 20200124], DOI: 10.1056/NEJMoa2001017 *

Also Published As

Publication number Publication date
WO2021203044A2 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
WO2021203044A3 (en) High-throughput assay for circulating antibodies against severe acute respiratory syndrome coronavirus 2
US11927596B2 (en) Assays for detecting the presence or amount of an anti-drug antibody
Zoghbi et al. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays
JP2019535015A5 (en)
Beghetto et al. Use of an immunoglobulin G avidity assay based on recombinant antigens for diagnosis of primary Toxoplasma gondii infection during pregnancy
JP6756611B2 (en) Competitive ligand binding assay to detect neutralizing antibodies
US20130130275A1 (en) Immunoassay methods and reagents for decreasing nonspecific binding
US20110189698A1 (en) Protein Biomarkers and Methods for Diagnosing Kawasaki Disease
RU2689143C1 (en) Improved diagnostic test for csfv antibodies
WO2006126008A3 (en) Improved immunoassay methods
WO2004025248A3 (en) Antibody pair screening methods
JPWO2011081075A1 (en) Method for extracting Staphylococcus aureus antigen, reagent for extraction of Staphylococcus aureus antigen, and method for determining Staphylococcus aureus
JP6515923B2 (en) Method of measuring creatine kinase MB isozyme and kit used therefor
WO2001066568A3 (en) Use of recombinant antigens to determine the immune status of an animal
Bernth-Jensen et al. Biological variation of anti-αGal-antibodies studied by a novel Time-Resolved ImmunoFluorometric Assay
WO2016005354A1 (en) Autoantibody profiling in aps
US8962256B2 (en) Surface-assisted hemagglutination and hemagglutination inhibition assays
EP1591791A3 (en) Diagnostic assay for human matrix gla-protein and its use as a biomarker
EP4253950A3 (en) Ce-western applications for antibody development
Fialova et al. Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum
Grace et al. Latex agglutination test for rapid on-site serodiagnosis of Japanese encephalitis in pigs using recombinant NS1 antigen
JP2023026069A (en) Immunoassay method for proteins with isoelectric point of 9.5 or greater, sample diluent used therefor, and immunochromatography kit
JP5093087B2 (en) Method for enhancing immune response with polyethylene glycol and urea
Moore et al. A plate-based histo-blood group antigen binding assay for evaluation of human norovirus receptor binding ability
TWI507688B (en) Method of measuring hemagglutinin of influenza virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21779952

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21779952

Country of ref document: EP

Kind code of ref document: A2